Dechra Veterinary Products has launched Cyclo Spray, an antibiotic spray for veterinary professionals treating hard to reach sites when handling cattle, sheep and pigs.
Dechra says the new product has been developed for use at any angle, even upside down.
Cyclo Spray (chlortetracycline hydrochloride 2.45%) is indicated for the treatment of superficial claw and hoof infections and the prevention of infections of superficial traumatic or surgical wounds.
Dechra Veterinary Products Brand Manager Emma Jennings said: "Vets dealing with livestock can often find that they are twisting themselves into awkward positions to get to hard to reach sites with traditional spray can treatments. Not only are they having to find the right angle to ensure the can works, but also potentially the treatment can drip or take time to dry.
"We've introduced Cyclo Spray to our portfolio to help combat some of those difficulties - it is a new 360 degree spray can allowing users to mark the site of application with confidence from whatever angle. It is non-drip, fast-drying with excellent adhesive characteristics and contains a non-toxic colouring agent."
Cyclo Spray is available in 211ml and 422ml can sizes. No withdrawal days are required for meat and milk.
To promote the launch of the new product, Dechra has also launched a competition giving entrants the chance to win a two day trip to London for two people to ride the London Eye and experience the capital from a 360 degree vantage point.
To enter the competition, with the prize including return rail travel, and dinner, bed and breakfast in a 4* hotel, visit www.dechra.co.uk to download an entry form.
Bimeda UK has announced that Endofluke 100mg Oral Suspension has been approved for use in dairy cows, with a milk withdrawal period of 45 days + 48 hours.
Endofluke is licensed for use in cattle and sheep and its active ingredient, triclabendazole (100mg/ml) kills all three stages of liver fluke.
Bimeda UK Sales Manager, Andrew Lane said: "This is great news for the UK's dairy farmers. Endofluke has long been favoured by British & Northern Irish farmers as a liver fluke treatment, due to its ability to offer complete chronic and acute fluke control in both sheep and cattle. It is proven to be highly effective against early-immature, immature and adult liver fluke, and to now be able to extend these benefits to dairy cows, is fantastic news for the UK's dairy farmers."
Endofluke is a POM-VPS product.
For more information, visit www.bimeda.co.uk or contact Bimeda UK Sales Manager Andrew Lane, on alane@bimeda.com or on 07917 208524.
Bayer is highlighting a new study which, the company says, proves that a 'metaphylactic' treatment approach to coccidiosis - when the animal has been infected, but before the disease has had chance to take hold - produces the best long term results1.
The research spanned a two year period where heifer calves on two farms that had previously experienced problems with naturally acquired coccidiosis, were divided into two groups. One group was treated with Baycox and one group remained untreated. The calves were then monitored for two years to gather the long term results following the coccidiosis treatment.
Sharon Cooksey BVSc, MRCVS, Bayer Animal Health Group Product Manager said: "The results demonstrated that treatment with Baycox at the right time significantly reduced the average age to first service by 24 days in comparison with the non-treated control group.
"Other key long term benefits following treatment included positive effects on certain fertility parameters, including overall pregnancy rate, the first service conception rate and average services per conception as well as a significant reduction in oocyst shedding in the treatment group."
Sharon says the take home message of the new research is the paramount importance of getting treatment right at the right time, before coccidiosis develops and causes any long term implications: "The positive impact on heifer development from correct subclinical coccidiosis treatment is clear to see in this research, with the reduction of days to first service alone being a powerful reason for farmers to seek veterinary advice."
Reference
Bimeda has launched Recocam, a 20mg/ml meloxicam preparation licensed for use as a single injection course in cattle, horses and pigs.
Bimeda's Head of Technical Services, Padraig Hyland MVB said: "Meloxicam's anti-inflammatory credentials and safety profile is well proven and it remains rightly popular with large animal vets. With our manufacturing expertise it makes sense to add this widely used product to our portfolio. Our aim is to provide a comprehensive range of both established standards and new innovative products for cattle and equine vets, and this is just another step in that process."
Bimeda says Recocam has a broad range of indications including acute respiratory infections, in combination with oral re-hydration in diarrhoea therapy and acute mastitis, for non-infectious locomotor disorders and lameness in pigs and alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders and pain relief associated with equine colic. In cattle Recocam can be given by single subcutaneous or intravenous injection.
BCF Technology has published a new clinical guide to the non-reproductive applications of ultrasound in farm animals.
Kimberly Palgrave BS BVM&S, created the booklet with the aim of helping veterinary surgeons understand the value in using ultrasound for more than reproduction purposes.
BCF says On farm ultrasound uses: Beyond pregnancy diagnosis provides key clinical descriptions and tips, along with normal and abnormal ultrasound images to show how ultrasound can aid in diagnosing various on-farm conditions you may be presented with, such as scanning the teat to detect stenosis, the umbilical area for an abscess, and even the thorax for help to diagnose BRD.
Kimberly said: "This clinical guide was created to help vets get more out of on farm ultrasound than just pregnancy diagnosis. There are a range of other uses for ultrasound on farm and this guide explains how to use your equipment for these applications. As always we are happy to receive feedback on any of our clinical materials."
To find out more or to get your copy of the guide, visit the learning section of the BCF website: www.bcftechnology.com
Zoetis has announced that Suvaxyn MH-One, its vaccine against Mycoplasma hyopneumoniae in pigs, has a revised licence allowing it to be administered from seven days of age with a two-week onset of immunity.
The company says this means that piglets can be protected by three weeks of age when they are commonly already infected with M. hyo. Duration of immunity extends well beyond the average UK pig slaughter age of 176 days.
Nigel Lodge, National Veterinary Manager for Zoetis in the UK said: "This is a significant step forward, recognising the full efficacy of the Suvaxyn MH-One vaccine against enzootic pneumonia. Trials have confirmed that use of Suvaxyn MH-One at seven days reduces lung lesions - even in the presence of maternally derived antibodies.
"The vaccine, which adds to our large and growing pig vaccine and product portfolio, also benefits from using adjuvants carbopol and squalane."
According to the company, the performance gains from early protection are shown in a field trial with 240 pigs injected at one week of age which showed significantly higher average daily weight gain, providing nearly 5 kg extra weight over the study period to 166 days.
MSD Animal Health has announced a new claim for Bovilis BVD and Bovilis IBR Marker Live vaccines which means they can be mixed and administered in a single syringe.
MSD says the new mixing claim will offer significant advantages in herd health planning when controlling two of the more important infectious diseases in cattle.
Bovine Viral Diarrhoea (BVD) and Infectious Bovine Rhinotracheitis (IBR) remain major threats to cattle health and productivity. Vaccinations are commonly given at housing and/or turnout, which are both busy times for veterinary surgeons and on the farm in the herd health planning calendar.
The mixed vaccines are suitable only for booster vaccinations of animals from 15 months of age previously vaccinated separately with Bovilis IBR Marker Live and Bovilis BVD. The mixed vaccine needs to be used within three hours.
MSD says the mixing procedure is clear and easy, but there is an instructional video here: http://www.msd-animal-health.co.uk/Mixing_bovilis_BVD_Bovilis_IBR-Marker_Live.aspx
The University of Bristol's School of Veterinary Sciences at Langford has opened a £2 million state-of-the-art dairy farm.
Wyndhurst Farm's dairy unit has undergone a major rebuild in order to provide a world-class practical teaching environment for around 600 veterinary students, as well as a facility that can be used to support research and the continual professional development of veterinary surgeons, farmers and others involved in the dairy industry locally, nationally and internationally. Professor Jo Price, Head of the School of Veterinary Sciences, said: "This is an exciting time for the Vet School. The new dairy unit will enable our undergraduate and postgraduate students to be taught in a world-class facility. It will provide the best standards of animal welfare for our dairy herd and will support our research on the prevention and treatment of diseases of farm animals."The farm, which is approximately 250 acres, includes numerous features to ensure high welfare standards. The dairy herd will be housed in deep sand bedded cubicles, with parts of the floors covered in soft rubber to protect the cows' feet and when housed cows will be fed a total mixed ration using grass, maize and whole crop wheat silages grown on the farm.Since the new facility has been built the farm's herd of Pedigree Holstein cows have increased in number from 110 to 180 cows and will soon reach 200, with each cow giving over 9,000 litres of milk per year. The farm also has a newly established breeding flock of 100 New Zealand Romney ewes. Since 2010 it has been managed by Velcourt Farm Management.
Norbrook Laboratories has launched Noroseal, a new teat sealant containing a unique anti-infective ingredient.
The company says that Noroseal, a 2.6g intramammary suspension, is the only teat sealant in the market-place in Europe to contain a PVP-Iodine excipient.
Dr Barry McInerney MVB, MRCVS, PhD, Norbrook GB Veterinary Advisor said: "Noroseal, with its unique formulation, offers vets a proven barrier against intramammary infections during the dry period.
"New bacterial infections occur most often during the first three weeks of drying off because the cow's natural keratin plug is not completely formed. Indeed, approximately 50% of teat canals are still open for up to seven days after drying off. Noroseal Teat Sealant will mimic the cow's keratin teat barrier offering immediate protection against infection. Additionally, the anti-infective ingredient, PVP-Iodine, complements the effectiveness of the teat-sealant components in the teat canal barrier."
Norbrook says that the estimated annual cost of mastitis to the UK dairy industry is in excess of £168M with a single case of clinical mastitis costing farmers approximately £178.00 per cow.
Dr McInerney added: "Clinical mastitis is a costly business but one that can be avoided if timely action is taken. There are various treatments available for dealing with mastitis but studies have shown that the risk of clinical mastitis may be reduced by up to 50% by using a combination of teat sealant and dry cow intramammary therapy. Noroseal is therefore an ideal combination with Norbrook's dry cow therapies such as Noroclox DC, Bovaclox DC Xtra and Bovaclox DC."
Noroseal is available in packs of 24 or buckets of 120 units. A range of promotional material is also available to veterinary practices via the Norbrook Sales Team.
The National Office of Animal Health has released two films to help industry and consumers understand issues surrounding the use of animal medicines in the food chain.
A film made for the food chain industry titled "Animal Medicines in Food Production - The Food Industry Perspective" has been produced to help industry understand the levels of awareness and concerns that consumers have.
A second film, "Animal Medicines in Food Production - Challenging the Myths" is aimed at consumers and looks at some of the myths surrounding the use of animal medicines in livestock production.
Phil Sketchley, Chief Executive of NOAH, said that while the public was generally supportive of the use of animal medicines in farm production, there was a knowledge gap among consumers about the way that medicines were used: "It was interesting to discover how much people knew about medicines in food production. There were some very positive attitudes among consumers, particularly towards the way British farmers care for their animals. But there were still some areas of concern, for example with the belief among a large number of people that growth hormones were still being used on UK farms, despite the fact they have been banned since 1988.
"The industry film should help people involved in food production understand what consumers are thinking when it comes to animal medicines. Animal health and welfare and ensuring sick animals are treated is a big issue, and food producers and retailers need to be able to communicate clearly with consumers on the subject of animal medicines.
"It is important there is transparency on all issues of animal health and welfare."
MSD Animal Health has reintroduced Zanil, the flukicide drench for cattle and sheep.
Based on the active ingredient oxyclozanide, MSD says Zanil is highly effective against the adult fluke responsible for chronic disease and - significantly for dairy farmers - is licensed for use in young, pregnant and lactating animals, with a 72-hour milk withhold period where milk is produced for human consumption.
MSD Animal Health veterinary advisor Matt Haslam said: "The latest independent data1 confirms that fluke is on the increase in UK cattle and sheep. The fluke problem is longstanding, but is being exacerbated by recent wet summer and autumn periods that have created ideal conditions for this parasite to proliferate and infect grazing livestock.
"Chronic liver fluke causes serious economic losses for livestock farmers. In dairy herds, for example, there will be a negative impact on fertility and milk production where cows are affected.
"It is important that farmers have access to the best treatment options given the size of the threat and the scale of potential losses. Zanil is used widely and effectively in Ireland in the control of fluke problems, and there is no known resistance to the active ingredient oxyclozanide. With its re-introduction into the country, we believe Zanil is unique as a flukicide-only treatment that is licensed for use in lactation and in the dry period for the treatment of adult fluke in dairy cows."
Zanil is an oral drench with POM-VPS authorisation, available from both animal health suppliers and veterinary practices. Dosage rate is 3ml per 10kg bodyweight in cattle, up to a maximum of 105ml, and 4.5ml per 10kg bodyweight in sheep, up to a maximum of 20ml.
See DEFRA emerging threats reports in sheep and cattle, Q1 2013: www.defra.gov.uk/ahvla-en/files/pub-survrep-sr0113.pdf
MSD Animal Health has launched Bovilis IBR Marker Inac, an inactivated marker vaccine for use in the control of Infectious Bovine Rhinotracheitis (IBR).
The company says the new product complements Bovilis IBR Marker Live and creates a range now offering greater simplicity and additional flexibility for veterinary surgeons seeking optimum control protocols for their clients' herds.
MSD Animal Health ruminant veterinary adviser Drew McGurren MRCVS said: "Farmer compliance is an important part of any successful vaccination programme. With this extended Bovilis IBR Marker programme, farmers can now start IBR vaccination of their cattle from three months of age with a single shot primary course of Bovilis IBR Marker Live, easily followed by boosters every six months using a single dose of either Bovilis IBR Marker Live or Bovilis IBR Marker Inac. Both primary course and boosters can be administered by the same intramuscular route.
"Alternatively, Bovilis IBR Marker Inac can be administered to cattle from three months of age as a primary course of two injections four weeks apart. The programme then follows a six monthly single dose booster regime.
"The availability of Bovilis IBR Marker Inac provides a simple control option in defined farm situations, not least where an alternative to the live vaccine is preferred or required. Overall, we see this development adding convenience, ease of use and flexibility for veterinary surgeons as they work with their clients to control a significant disease threat in dairy and beef cattle in the UK."
Bovilis IBR Marker Inac is a prescription-only medicine (POM-V). The product is available from wholesalers now in 10 and 50 dose vials. For further information, contact the MSD Animal Health Veterinary Support Group on 01908 685685.
Virbac has been granted a Limited Marketing Authorisation in the UK for its Gudair vaccine, indicated for the active immunisation of sheep and goats against Mycobacterium avium subspecies paratuberculosis (MAP).
MAP is the causal organism for Johne's Disease, a chronic infection of the intestinal system for which there is no cure.
According to Virbac, Johne's Disease enters most flocks following the introduction of infected stock, often breeding rams, bought at markets without checks on disease provenance. It is then spread by the faeces of often apparently healthy animals but which can contain huge numbers of MAP. The main clinical sign is a thin ewe resulting in poor productivity followed by inevitable death. It can be passed between sheep and cattle.
Ovine Johne's Disease (OJD) in sheep is widespread in Australia where annual death rates of up to 17% have been seen in infected flocks. Virbac says that trials conducted there have demonstrated that vaccination with Gudair can reduce the number of deaths due to OJD by 90% and reduce the numbers of OJD-causing organisms excreted in sheep faeces by 90%.
Ken Sibley MRCVS, Technical Advisor at Virbac says that the number of infected flocks in the UK is unknown and the disease often remains undiagnosed: "Johne's Disease can be a significant cause of loss in infected sheep flocks because of reduced productivity and high culling rates. Vaccination provides the only possible assurance when sourcing sheep from potentially infected flocks and will help to reduce losses from the disease should a farmer inadvertently introduce sheep into an infected flock.
"Lambs identified as replacements should generally be vaccinated between 4 and 16 weeks of age, subcutaneously behind the ear. Sheep over 16 weeks of age can also be vaccinated as this will reduce shedding of organisms in infected animals while bought-in replacements can be vaccinated on arrival at the farm. Sheep require only one vaccination for their lifetime.
"Following its success in Australia, we are delighted to be able to offer Gudair to veterinary surgeons in the UK."
For further information, contact your Virbac territory manager or call: 01359 243243
BCF has released a new bovine foetal sexing quick guide as a free download from the farm animal learning section of the company's website - www.bcftechnology.com.
To help vets learn the skill of foetal sex determination with ultrasound, the guide includes:
BCF says that using ultrasound for foetal sex determination can be useful to herd management programmes: you can estimate the number of replacement heifers, further justify the culling of a cow with chronic disease (mastitis, lameness etc.) and determine pricing for a sale and/or purchase.
The guides have been created by BCF in-house vet Kimberley Palgrave who said: "The bovine foetal sexing guide was created with the aim of giving vets a few tips to help them develop confidence in foetal sex determination using ultrasound. Hopefully this guide can help people feel more assured in their technique and enable them to obtain additional information that the farmer can use in their herd management programme."
Zoetis has relaunched a broad spectrum intramammary treatment for clinical mastitis, as Lincocin Forte S.
For vets seeking to prescribe an alternative first-choice tube, independent mastitis authority Dr Andrew Bradley suggests it could be a logical, efficacious option, offering the combination of two active ingredients (lincomycin and neomycin) not available in other intramammary tubes.1
Zoetis points to studies which show that In combination, these have been found to have much higher efficacy than the sum of the two parts against Staphylococci aureus.2&3
The company says Lincocin Forte is effective against Gram positive and Gram negative pathogens, in particular staphylococcus, streptococcus and coliform bacteria.
In trials, the treatment produced clinical cure rates 21% higher than an ampicillin-cloxacillin comparison in undifferentiated mastitis cases. As first choice treatment for S uberis clinical mastitis, bacteriological cure rates were similar to a penicillin-streptomycin comparison.4 Against S aureus, aesculin-positive streptococci, and E coli, combined clinical-bacteriological cure rates were 175%, 32% and 21% higher respectively with Lincocin Forte S than ampicillin-cloxacillin treatment.
Zoetis vet Jude Roberts said these findings underpin the treatment's relaunch and its suitability as a first choice therapy for new clinical mastitis cases.
Lincocin Forte S is a water-based formulation, which Jude says helps achieve good distribution in the udder and can be easier to infuse that oil-based tubes, particularly into hardened quarters associated with E coli infections.
Dr Bradley adds that water-based formulation is likely to be less irritant to udder tissues than oil-based tubes, and may improve distribution. He also suggests that "not being a fluoroquinolone or 3rd/4th generation cephalosporin may also help vets fulfil their 'appropriate and justified' prescribing responsibilities."
The recommended treatment is one 10ml syringe per infected quarter at each of three consecutive milkings. Milk from treated cows can be sold for human consumption 84-hours after the last treatment.References:
Bimeda has announced the launch of a new teat seal which the company claims offers a significant return on investment and an opportunity for veterinary surgeons to prompt farmers to re-evaluate their dry cow therapy and mastitis control.
Bimeda's vet and head of technical services, Padraig Hyland MVB said: "Boviseal is proven to dramatically reduce mastitis in the 100 days post calving¹. Adding competition to the market will encourage farmers to re-assess their dry cow and mastitis strategies.
"The UK launch of Boviseal is a great opportunity for vets to raise the issue of the damage and cost of mastitis, and the potential savings by the correct use of a seal. Boviseal is the number one selling teat seal in the Republic of Ireland, with 2/3 of the Irish dairy cows sealed annually²."
Padraig says the evidence of the value from combined sealing and antibiotic therapy is all too clear when it comes to dry cow therapy. He cites a case study at Waterwheel Farm in Donegal, Ireland which delivered a 300% return on investment: "Combined therapy might sound costly but this two year study saw annual mastitis cases fall dramatically, from 26 per 100 cows to 9 per 100³.
"Defra figures indicate that mastitis is the most costly disease problem that UK dairy farmers face, with a typical case costing £175.00 4. When you compare that against the cost of treatment for the herd, there's no real counter argument in my opinion."
Boviseal contains 65% Bismuth Subnitrate. Padraig says the effectiveness of teat sealing is proven but correct administration is key: "It is important to note that the conventional practice of massaging into the udder after infusion is not employed - the teat seal must stay in the teat canal."
For details on best application practices, the company has developed a website, www.boviseal.co.uk with a video demonstration for correct infusion.
For further information, visit the website or contact Bimeda on 01248 725400.
References
Chanelle has announced the launch of Ketamidor 100 mg/ml Solution for Injection (ketamine), licensed for use in cats, dogs, horses, cattle and swine in the UK and Ireland.
The company says the new product provides a versatile addition to anaesthetic regimes. It can be used in combination with other widely-used anaesthetics and sedatives. Chanelle says it also has analgesic properties that make it particularly beneficial to include in anaesthetic protocols when carrying out painful surgical procedures.
Ketamidor 100mg/ml Solution for Injection has a zero day withdrawal period for milk and meat when used in cattle and pigs, allowing high welfare standards to be maintained without compromising economic returns.
According to Chanelle, ketamine is now experiencing a resurgence of interest as its analgesic properties and minimal impact on spontaneous respiration become increasingly appreciated.1
Angela Wilkin, Chanelle UK's Sales and Marketing Manager said: "Ketamidor makes a great addition to our portfolio of pain management products. Our territory managers are looking forward to speaking to those vets who are already accustomed to using ketamine and those that may be considering adding it to their current protocols."
The RSPCA has announced that it will continue its fight to stop the Government's planned cull of badgers after MPs voted against an opposition motion to reverse the Government's strategy aimed at combating bovine TB.
MPs voted 299 to 250 against proposals to stop the cull going ahead in two pilot areas in Somerset and Gloucestershire - a narrower margin than the Government has in the House of Commons despite the three-line whip enforced.
RSPCA chief executive Gavin Grant said: "We fight on. This vote flies in the face of scientific and public opinion. We are grateful to those MPs who spoke out against the cull and particularly those who defied the Government's three line whip.
"There can be little doubt that had MPs been free to express their views through a free vote there would have been a large majority against the cull as there was last October.
"The only real way forward is the vaccination of both cattle and badgers, better biosecurity and control of cattle movements."
The debate follows a report issued by the EFRA select committee which said more investment is urgently needed into vaccination as a solution for bovine TB.
One of the earliest decisions of this government was to cancel five of the six badger vaccination projects planned - a policy the RSPCA believes was short-sighted.
RSPCA chief executive Gavin Grant said: "Much more needs to be done to bring forward the timetable for the development of effective oral vaccination programmes for both cattle and badgers as the EFRA report says.
"Meanwhile we stand ready to work with those who want to vaccinate and save lives rather than cull and kill."
As the open season for shooting badgers begins on 1 June, the British Veterinary Association is reiterating its support for the planned badger cull pilots as part of the overall bovine TB eradication strategy in England.
Although the shooting of badgers is not expected to start until later in the season the BVA says it is responding to activity amongst those who oppose the cull and appealing to them to allow the necessary scientific work to take place unhindered in the two pilot cull areas.
The association points to the evidence base behind the policy - data from the Randomised Badger Culling Trials (RBCTs) - which shows that bovine TB in cattle can be reduced by around 16% in areas where a targeted, humane badger cull has taken place. The pilot culls will use different culling methods to the RBCTs and are therefore being monitored by the Independent Expert Panel made up of experts in veterinary pathology, animal welfare physiology, wildlife ecology, badger behaviour, wildlife management, ecological theory, statistics, and marksmanship.
Peter Jones, President of the BVA, said: "We have not taken the decision to support the pilot badger culls lightly; we have considered all of the scientific evidence, which supports the management of bovine TB in badgers in order to reduce the incidence of the disease in cattle.
"We accept that there is a gap in our knowledge, which is whether controlled shooting can deliver a badger cull humanely and safely, and to the same degree of effectiveness as cage trapping and shooting. That is what the pilots are designed to address and why is it important that they are allowed to go ahead unhindered.
"We understand that this is a highly emotional issue but we must be able to gather the evidence to enable future policy decisions to be based on science."
The Veterinary Medicines Directorate (VMD) has granted MSD Animal Health a provisional UK marketing authorisation for Bovilis SBV, the first vaccine specifically targeting the Schmallenberg virus (SBV) in cattle and sheep.
SBV, which emerged in late 2011, is transmitted via insect vectors, mainly midges and causes transient clinical symptoms in adult cattle and sheep, such as fever, diarrhoea and reduced milk yield, as well as congenital malformation in newborn calves and lambs. As of March 31st 2013, 1753 cases of SBV had been confirmed throughout the UK. SBV has now been detected in every county in England and Wales.
Andras Bolcskei, Country Manager, MSD Animal Health UK said: "On behalf of Merck MSD, we would like to thank the VMD for its partnership and support to fast track the availability of Bovilis SBV to the market. There was a tremendous urgency for a SBV vaccine in the UK especially given the marked increase in confirmed cases over the past year and the increasing importance to help control this devastating disease."
MSD says that studies it conducted in support of the provisional marketing authorisation showed that all animals responded with formation of virus neutralizing antibodies. During the studies, reduced viraemia against SBV was observed in sheep vaccinated once and prevention of viraemia was observed in cattle vaccinated twice, whereas all animals in the control groups developed infection and became viraemic. In studies to date, Bovilis SBV has been shown to be efficacious in cattle and sheep.
The vaccine is based on wild-type SBV that has been inactivated and contains an adjuvant that stimulates the immune response.
The vaccine will be available in 20ml and 100ml vials. Bovilis SBV is indicated for the active immunisation of cattle to prevent viraemia against SBV and for the active immunisation of sheep to reduce viraemia against SBV.
MSD says it is working diligently to expedite stocks to the UK, and expects Bovilis SBV to arrive in the UK in the coming weeks.
BCF has launched a series of instructional videos demonstrating how to perform an ultrasound examination of the bovine reproductive tract, now available online.
The videos were developed by BCF's in-house vet, Kimberly Palgrave, in collaboration with the University of Bristol Veterinary School. They show everything from machine set up and controls, to scanning techniques and features identified in pregnant and non-pregnant cows.
One hour of CPD can be earned by completing a self-assessment quiz after watching the videos.
Kimberly said: "Following the success of the small animal series of instructional videos, we were keen to bring something similar to the bovine market. Our aim for these videos is to give vets a resource to help them either transition from manual palpation to ultrasound or improve their existing ultrasound skills and gain confidence in their technique, as well as being a useful teaching resource for veterinary students. As always, we welcome feedback and suggestions for the future."
To see the videos, visit the farm animal learning section of the BCF website www.bcftechnology.com.
MSD Animal Health has launched a new range of vaccination equipment to help sheep and cattle producers administer its portfolio of farm animal vaccines as effectively, cleanly and safely as possible.
The new vaccinators all incorporate the Sterimatic system, which is designed to take the worry out of administering injections to livestock by delivering an accurate dose of any given product, whilst also cleaning and protecting the needle automatically. MSD says the Sterimatic system also decreases the potential for disease transmission, minimises the risk of infection and abscessing at the vaccination site, and reduces needle-stick injuries.
The new equipment is colour-coded and ergonomically designed for comfort in the hand and comes in clear, sterile bags that list the recommended vaccines for use with each vaccinator.
The new vaccinators are now available from animal health product wholesalers.
To what extent changing diets and adding novel feed additives can cut emissions from beef cattle is being investigated in a new three-year research project.
EBLEX, the organisation for beef and sheep producers in England, has teamed up with Scotland's Rural College, SRUC, in Edinburgh, to look at how changes to feeding regimes can improve efficiency and drive business profitability, while reducing greenhouse gas (GHG) emissions produced as a by-product of rumination.
Steers will be finished on either concentrate based or forage based diets, each with two different feed additives, such as vegetable oils. The role of the rumen microbial population in the responses will be measured to look at how rumen function changes according to diet, additive and breed. Results will be related to the greenhouse gas emissions and feed efficiency, as well as long-term effects of feed additives.
Dr Mary Vickers, senior livestock scientist with EBLEX said: "The animals will be moved into specialist chambers for short periods of time where their emissions can be captured.
"In addition, when they are accessing rations from group pens, special plastic hoods over the feeding stations can measure the specific emissions at those times. Measuring emissions, rumen function, feed intake and growth rates can help us build a picture of any effect the additives have.
"The ultimate aim is to ensure the cattle are having their full nutritional needs met in an efficient, cost effective way while minimising the emissions produced."
In addition, carcase quality, meat quality and shelf life will also be recorded to ensure quality of the final product is maintained. The outcomes of this project will provide producers with independent advice about the efficacy of two feed additives fed in a range of commercial conditions.
Novartis Animal Health has announced the launch of a new campaign called Prepare, Predict, Prevent and designed to raise awareness of blowfly strike management in sheep.
The campaign will include new industry research, an expert-led report, and information tailored to farmers, veterinary surgeons and SQPs. The campaign is aimed at improving awareness of blowfly strike management, with a particular focus on prevention.
In the UK, blowfly strike (myiasis) occurs on over 80 per cent of sheep farms2. If untreated, strike can severely affect the welfare of infested sheep, and may result in death. For farmers, poor management of blowfly strike brings economic costs in terms of the loss of animal, production losses and in terms of treatment and control of the disease, which is easily spread.
Furthermore, previous research from the University of Bristol4, which simulated the pattern of parasite growth in different climate-dependent environments, showed that an increase in average temperature of 3 degrees Celsius would be enough to quadruple the incidence of strike in ewes and double the rate in lambs. This is a growing concern, with climate change models for the UK suggesting that over the next 50 years summer temperatures are set to increase by 1.5 degrees Celsius and winter temperatures by 2.5 degrees Celsius5.
Research conducted at the 2013 Animal Health Distributors Association (AHDA) Annual Conference indicated that, in the past five years, many believe the blowfly strike season is lasting longer and beginning earlier in the year, with the majority of early reported cases occurring unexpectedly in March. The findings have prompted a wider survey from Novartis Animal Health, which is urging SQPs, farmers and key opinion leaders nationwide to contribute answers at: www.farmanimalhealth.co.uk/fleecebind-questionnaire.
Katherine Openshaw, Ectoparasiticides Category Manager at Novartis Animal Health, said: "This has always been a serious issue for the sheep industry and elevated temperature is likely to bring about increased levels of blowfly strike and a longer season.
"We recognise the need to evolve attitudes towards parasite control and to provide farmers and prescribers with the knowledge and tools needed to facilitate a better management of blowfly strike. The 'Prepare, Predict, Prevent' campaign is all about simple, yet effective, measures to prevent the occurrence of blowfly strike, which can be enough to ensure farmers are protected from the potentially devastating impacts of flock infestation, offering season peace of mind.
"We have developed a range of materials to aid prescribers in promoting preventative solutions to farmers; these include farmer leaflets, posters and counter displays. We will also be offering training support so prescribers are best equipped to help farmers make informed decisions about preventative blowfly solutions."
Animalcare Ltd has launched Marbocare (marbofloxacin) 100mg/ml solution for injection, a third-generation fluoroquinolone for the treatment of E.coli mastitis and bovine respiratory disease (BRD) in cattle, and Metritis Mastitis Agalactia in pigs.
The company highlights the product's unique flexible dosage regimen of once daily injections for 3 days against E.coli mastitis and BRD, plus a single intramuscular (IM) high dose (8mg/100kg) for BRD.
Animalcare says this regimen, coupled with the flexibility of administration afforded by all three injection routes (intravenous IV, subcutaneous SC and IM), a low volume dose and good syringeability, all combine to offer ease of use; resulting in a reduction in handling and less stress for the cattle.
Developed for veterinary use only, Marbocare has broad spectrum activity against Gram+ve and Gram-ve pathogens. Animalcare says the product is especially effective against E.coli mastitis and the key bacterial pathogens associated with BRD, as well as M.bovis.
Marbocare has milk withdrawal times of 36 hours after the last treatment following the 3 day course and 72 hours after a single shot for BRD. Meat withdrawal is 6 days after multiple injections and 3 days after the single shot.
Marbofloxacin has proven efficacy in a comparative international, multi-centre, controlled, randomised field trial1 in 62 dairy cows with E.coli mastitis. Marbofloxacin cure rates were significantly higher than the control product. In respiratory disease it showed a more rapid clinical response in comparison to tilmicosin2, ceftiofur3 and oxytetracycline4. Marbofloxacin was shown to be well tolerated, leading to a fast return to appetite, liveweight gain and associated welfare benefits.
Marbocare is also licensed in the treatment of Metritis Mastitis Agalactia syndrome in pigs, given by IM injection, with a 4 day meat withdrawal.
Tony Liepman, Product Manager from Animalcare said: "Marbocare is competitively priced whether used on its own or alongside a single-dose anti-inflammatory such as Emdocam (meloxicam)."
Marbocare is a POM-V licensed product presented in 50 and 100ml multi-dose vials.